Risultati della ricerca - Yamo Deniz, MD

  • Mostra 1 - 1 risultati su 1
Raffina i risultati
  1. 1

    Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions di Ian D. Pavord, MD, Michael E. Wechsler, MD, William W. Busse, MD, Christian Domingo, MD, Changming Xia, PhD, Rebecca Gall, MD, Nami Pandit-Abid, PharmD, Juby A. Jacob-Nara, MD, DHSc, Amr Radwan, MBBChir, Paul J. Rowe, MD, Yamo Deniz, MD

    Pubblicazione 2025-08-01

    Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, mo...

    Descrizione completa

    Testo
    Articolo